Trevi Therapeutics to Participate in Upcoming March Investor Conferences
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
clinicaltrialsarena5d
Trevi Therapeutics enrols all subjects in trial of Haduvio for chronic cough in IPF
Trevi Therapeutics has finished enrolling subjects in a trial of investigational Haduvio for treating chronic cough in IPF ...
B.Riley Financial Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...
Trevi Therapeutics Completes Enrollment For Phase 2B CORAL Trial Of Haduvio In Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
Topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn., Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc.